[Memorandum to Presidential Advisory Council on HIV and AIDS Research Committee Members from Bruce G. Weniger]
Incentives and Disincentives for Vaccine Development: A Biotech Perspective Safety * Safety parameters must be determined, with risk/benefit taken into consideration before large scale clinical trials of a preventive vaccine are begun. * A whole gpl20 depleted inactivated virus vaccine has been injected into over 1,000 HIV seropositives with no serious treatment related adverse events. Page 5
About this Item
- Title
- [Memorandum to Presidential Advisory Council on HIV and AIDS Research Committee Members from Bruce G. Weniger]
- Author
- Weniger, Bruce
- Canvas
- Page 5
- Publication
- 1997-01-10
- Subject terms
- memorandums
- Series/Folder Title
- Government Response and Policy > Presidential > Clinton Administration > Presidential Advisory Council on HIV and AIDS (U.S.) (PACHA) > Meetings and correspondence
- Item type:
- memorandums
Technical Details
- Collection
- Jon Cohen AIDS Research Collection
- Link to this Item
-
https://name.umdl.umich.edu/5571095.0495.212
- Link to this scan
-
https://quod.lib.umich.edu/c/cohenaids/5571095.0495.212/10
Rights and Permissions
The University of Michigan Library provides access to these materials for educational and research purposes, with permission from their copyright holder(s). If you decide to use any of these materials, you are responsible for making your own legal assessment and securing any necessary permission.
Related Links
IIIF
- Manifest
-
https://quod.lib.umich.edu/cgi/t/text/api/manifest/cohenaids:5571095.0495.212
Cite this Item
- Full citation
-
"[Memorandum to Presidential Advisory Council on HIV and AIDS Research Committee Members from Bruce G. Weniger]." In the digital collection Jon Cohen AIDS Research Collection. https://name.umdl.umich.edu/5571095.0495.212. University of Michigan Library Digital Collections. Accessed June 11, 2025.